Drug intelligence / Profile preview

S-Carvedilol

Development stage: Phase 3
Lead developer: AHN-GOOK PHARMACEUTICAL
Modality: Small Molecules
Administration: Oral

Overview

AGSCT101 is the S-enantiomer of carvedilol, developed by Ahn-Gook Pharmaceutical as an incrementally modified drug product for the treatment of essential hypertension. It acts as a beta-adrenoceptor antagonist (beta-blocker), targeting β-adrenoceptors to lower blood pressure. The drug is classified as an antihypertensive and is administered orally. It was launched in South Korea for essential hypertension before March 2018 and represents a new formulation rather than a new molecular entity[1][4][5][7].

Other names: s-carvedilol

Targets

ADRB1 (β1)ADRB2 (β2)

Beyond the preview

Go deeper on S-Carvedilol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on S-Carvedilol.

Explore the full profile